Premium
A possible inhibitory action of diaminodiphenyl sulfone on tumour necrosis factor‐α production from activated mononuclear cells on cutaneous lupus erythematosus
Author(s) -
Abe M.,
Shimizu A.,
Yokoyama Y.,
Takeuchi Y.,
Ishikawa O.
Publication year - 2008
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/j.1365-2230.2008.02864.x
Subject(s) - peripheral blood mononuclear cell , medicine , tumor necrosis factor alpha , lipopolysaccharide , immunology , necrosis , dapsone , lupus erythematosus , in vitro , pharmacology , pathology , biology , antibody , biochemistry
Summary Background. We have previously reported that diaminodiphenyl sulfone (DDS; dapsone) can bring about significant clinical improvement in patients with cutaneous lupus erythematosus (CLE). However, the pharmacological actions of DDS in the skin lesion of patients with CLE are still unknown. Objective. In this study, we aimed to clarify the pharmacological actions of DDS on CLE. Methods. We conducted an in vitro study to examine the effects of DDS on the mRNA expression and production of cytokines on lipopolysaccharide‐stimulated peripheral blood mononuclear cells. Results. DDS suppressed mRNA expression of tumour necrosis factor (TNF)‐α and significantly decreased the level of TNF‐α in culture supernatant. Conclusions. DDS may exert an anti‐inflammatory action by suppressing TNF‐α produced by activated mononuclear cells.